Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials - 09/05/15
Alice Gottlieb, MD, Tufts Medical Center, Boston, MA, United States; Bruce Strober, MD, University of Connecticut Health Center, Farmington, CT, United States; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Roland Kaufmann, MD, Department of Dermatology, Venereology and Allergology, Goethe-University, Frankfurt, Germany; David Pariser, MD, Eastern Virginia Medical School, Norfolk, VA, United States; Redzinaldas Narbutas, MD, Vilnius University Hospital Clinic, Vilnius, Lithuania; Judit Nyirady, MD, Novartis, East Hanover, NJ, United States; Yang Zhao, PhD, Novartis, East Hanover, NJ, United States; Mary Helen Tran, PhD, Novartis, East Hanover, NJ, United States; Lori McLeod, PhD, RTI Health Solutions, Raleigh, NC, United States; Dawn Odom, MS, RTI Health Solutions, Research Triangle Park, NC, United States; Boni Elewski, MD, University of Alabama at Birmingham, Birmingham, AL, United States
Le texte complet de cet article est disponible en PDF. Funding by Novartis. |
Vol 72 - N° 5S1
P. AB250 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?